Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

Gilead Sciences has said it plans to challenge patents held by the US government on the use of its HIV drug Truvada for pre-exposure prophylaxis (PrEP). In a move that will incense critics who ...

Gilead (GILD) Sciences presented the first data ... when compared to background HIV incidence and once-daily oral Truvada in a broad and geographically diverse range of people, the company stated.

Though sales were modest (Table 1), Emtriva added layers to Gilead's HIV portfolio. The combined-dose pill of Emtriva and Viread, launched as Truvada in third-quarter 2004, brought in $68 million ...